ReviewStem cell research & therapy2025
Evaluation of safety and efficacy: a case series of chronic limb-threatening ischemia treated with endovascular revascularization and umbilical cord mesenchymal stem cell therapy.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere chronic limb-threatening ischemia has significant challenges, leading to poor outcomes, including amputation and death. By guiding angiosome blood flow to the ulcerated foot, a therapeutic combination of endovascular revascularization and mesenchymal stem cells can achieve a good outcome.
objectiveTo describe the efficacy and safety of combination endovascular treatment and umbilical cord mesenchymal stem cell (UCMSC) treatment for chronic limb threatening ischemia.
methodsThe design of the study was a longitudinal study, serial case report and prospectively observed pilot study. All patients received intramuscular UCMSC with a dosage of 1-2 million cells per kilogram of body weight then followed by endovascular intervention based on angiosome guided. We monitored the patients efficacy and safety for 12, 18, and 24 months.
resultThis study involved six patients. All patients have an ankle brachial index below 0.4, and 83.3% of patients have diabetes mellitus, high creatinine level with an average of 1.64 mg/dl, and severe pain scores based on the Visual Analog Scale (VAS) of more than 7. 6th month was the time where the creatinine median was reduced, the ABI median was increased, the wound improvement started to happen. While the pain median score was reaching zero in 12 months of observation. 24 months revealed significant improvements in patient outcomes across pain scores, creatinine levels, and ankle-brachial index (ABI) with p < 0.05.
conclusionThe new technique, unique and innovative research, for using combination treatment of intramuscular UCMSC and modern endovascular procedures based on angiosome concept showed fast and safe wound healing, reduce rest leg pain, and increase ABI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.